Study study type PathologyT1T0Patientssample sizesROB Results

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
IMpower-130 (all population), 2019
  NCT02367781
RCTnon squamous - mNSCLC - L1 - all populationatezolizumab plus carboplatin plus nab-paclitaxel (ACnp)carboplatine plus nab-paclitaxel (CnP)first-line therapy for patients with stage IV non-squamous nonsmall- cell lung cancer and no ALK or EGFR mutations who have not previously received chemotherapy483 / 240some concern
conclusif
  • demonstrated 20 % decrease in deaths (OS) (PE)
  • demonstrated 35 % decrease in progression or deaths (PFS) (PE)

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
IMpower-130 (WT), 2019
  NCT02367781
RCTnon squamous - mNSCLC - L1 - Wild Type (WT)atezolizumab (ACnP) plus carboplatine plus nab-paclitaxelcarboplatine plus nab-paclitaxelfirst-line therapy for patients with stage IV non-squamous nonsmall- cell lung cancer who have not previously received chemotherapy. (EGFRwt and ALKwt)451 / 228some concern
conclusif
  • demonstrated 21 % decrease in deaths (OS) (PE)
  • demonstrated 36 % decrease in progression or deaths (PFS) (PE)
  • statistically significant 1.4-fold increase in DOR